US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.3100

+0.01344.52%

Post-market: 0.31000.00000.00%19:46 EDT

Volume:404.78K

Turnover:122.40K

Market Cap:1.94M

PE:-0.09

High:0.3167

Open:0.3002

Low:0.2880

Close:0.2966

Loading ...

Overview Company News Filings

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharmaceuticals Files Provisional US Patent to Treat Prostrate Cancer

MT Newswires Live

BRIEF-Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate Cancer

Shuttle Pharmaceuticals- Files Provisional Patent Application for Psma Ligand Conjugates to Treat Prostate Cancer

THOMSON REUTERS

Shuttle Pharmaceuticals files provisional patent application with USPTO

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharmaceuticals Holdings Inc - on March 21, Enters Consulting Agreement With Bowery Consulting - SEC Filing

THOMSON REUTERS

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

THOMSON REUTERS

BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock

Shuttle Pharmaceuticals Holdings Inc - Offering up to 10,000,000 Shares of Common Stock

THOMSON REUTERS

BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement

Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement

THOMSON REUTERS

Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF

Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program

THOMSON REUTERS

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SHPH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SHPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SHPH\",,,,,undefined,":{"symbol":"SHPH","market":"US","secType":"STK","nameCN":"Shuttle Pharmaceuticals Inc","latestPrice":0.31,"timestamp":1745611200000,"preClose":0.2966,"halted":0,"volume":404784,"hourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.31,"latestTime":"19:46 EDT","volume":26404,"amount":7950.7017,"timestamp":1745624777585},"delay":0,"floatShares":5554536,"shares":6257693,"eps":-3.304118,"marketStatus":"Market Closed","change":0.0134,"latestTime":"04-25 16:00:00 EDT","open":0.3002,"high":0.3167,"low":0.288,"amount":122403.38665824001,"amplitude":0.096763,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.304118,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1661918400000,"exchange":"NASDAQ","adjPreClose":0.2966,"preHourTrading":{"tag":"盘前","latestPrice":0.3001,"preClose":0.2966,"latestTime":"09:27 EDT","volume":8686,"amount":2651.07733848,"timestamp":1745587661676},"postHourTrading":{"tag":"盘后","latestPrice":0.31,"preClose":0.31,"latestTime":"19:46 EDT","volume":26404,"amount":7950.7017,"timestamp":1745624777585},"volumeRatio":0.1781929046008203},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SHPH\",,,,,undefined,":{"symbol":"SHPH","floatShares":5554536,"roa":"-113.74%","roe":"-383.84%","lyrEps":-3.186207,"volumeRatio":0.1781929046008203,"shares":6257693,"dividePrice":0,"high":0.3167,"amplitude":0.096763,"preClose":0.2966,"low":0.288,"week52Low":0.23,"pbRate":"2.74","week52High":4.7104,"institutionHeld":0,"latestPrice":0.31,"eps":-3.304118,"divideRate":0,"volume":404784,"delay":0,"ttmEps":-3.304118,"open":0.3002,"prevYearClose":0.859,"prevWeekClose":0.2535,"prevMonthClose":0.389,"prevQuarterClose":0.389,"fiveDayClose":0.2535,"twentyDayClose":0.3949,"sixtyDayClose":0.751},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SHPH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529307573","title":"Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529307573","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529307573?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:15","pubTimestamp":1745266500,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., April 21, 2025  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 2:30 p.m. Pacific Time . Anatoly Dritschilo, M.D., Chairman of the Board of Directors and Chief Scientific Officer of Shuttle Pharma, will be hosting the presentation and answering questions at the conclusion.Dr. Dritschilo’s presentation will focus on providing an overview and update on the Company’s ongoing Phase 2 trial of Ropidoxuridine and RT for treatment of patients with glioblastoma as well as advancements being made in the Company’s Shuttle Diagnostics subsidiary which aims to develop pretreatment diagnostic blood tests and imaging agents for prostate cancer patients.Planet MicroCap Showcase: VEGAS 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-present-planet-microcap-201500782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2526354704","title":"Shuttle Pharmaceuticals Files Provisional US Patent to Treat Prostrate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354704","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354704?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:41","pubTimestamp":1744321312,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals  said late Thursday it filed a provisional US patent for prostate-specific membrane antigen ligand conjugates to treat prostrate cancer.The patent, \"PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy,\" could advance diagnostic and therapeutic programs for patients with metastatic castration-resistant prostate cancer, the company said.PSMA is expressed on the surface of cancer cells, and ligands targeting the antigen are smaller and present potential advantages for more efficient drug delivery, according to a company statement.Shares are up nearly 10% in after-hours activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2526544957","title":"BRIEF-Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526544957","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526544957?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:52","pubTimestamp":1744318378,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Files Provisional Patent Application For PSMA Ligand Conjugates To Treat Prostate CancerApril 10 (Reuters) - Shuttle Pharmaceuticals Holdings Inc SHPH.O:SHUTTLE PHARMACEU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2526549028","title":"Shuttle Pharmaceuticals- Files Provisional Patent Application for Psma Ligand Conjugates to Treat Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526549028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526549028?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:29","pubTimestamp":1744316966,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2526154919","title":"Shuttle Pharmaceuticals files provisional patent application with USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2526154919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526154919?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:10","pubTimestamp":1744315854,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (SHPH) announced the filing of a provisional patent application with the United States Patent and Trademark Office entitled...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-files-provisional-patent-application-with-uspto?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-files-provisional-patent-application-with-uspto?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2526546297","title":"Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526546297","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526546297?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:01","pubTimestamp":1744315260,"startTime":"0","endTime":"0","summary":"Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs. Dr. Alan Kozikowski, internationally acclaimed pioneer in the discovery of a critical PSMA targeting ligand for clinical applications is co-inventor. Theranostic molecule designed to preferentially target prostate cancer cells to the effects of radiation and chemotherapeutic agents. The filing comes through Shuttle Pharma’s collaboration with internationally renowned medicinal chemist, Dr. Alan Kozikowski. Dr. Kozikowski’s original medicinal chemistry research performed in collaboration with Professor Joseph Neale and conducted at Georgetown University Medical Center were a component in the creation of both Pylarify and Pluvitco.“I believe a significant opportunity exists for PSMA ligands for prostate cancer diagnosis and treatment,” commented Anatoly Dritschilo, MD, Shuttle Pharma’s Chairman and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-developing-pretreatment-diagnostic-200100665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2522880627","title":"Shuttle Pharmaceuticals Holdings Inc - on March 21, Enters Consulting Agreement With Bowery Consulting - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880627?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:21","pubTimestamp":1742934106,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2519869930","title":"Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2519869930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519869930?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:10","pubTimestamp":1741896616,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA5WKDVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2517161219","title":"BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161219","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517161219?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:42","pubTimestamp":1741178543,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common StockMarch 5  - Shuttle Pharmaceuticals Holdings SHPH.O:SHUTTLE PHARMACEUTICALS HOLDINGS INC - OFFERING UP TO 10,000,000 SHARES OF COMMON STOCKSource text: [ID:n0001493152-25-009106]Further company coverage: SHPH.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2517918036","title":"Shuttle Pharmaceuticals Holdings Inc - Offering up to 10,000,000 Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2517918036","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517918036?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:50","pubTimestamp":1741175459,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN15H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2516300822","title":"BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300822?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:26","pubTimestamp":1740781613,"startTime":"0","endTime":"0","summary":"BRIEF-Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan AgreementFeb 28  - Shuttle Pharmaceuticals Holdings Inc SHPH.O:SHUTTLE PHARMACEUTICALS HOLDINGS INC - ENTERS $2 MILLION REVOLVING LOAN AGREEMENTSource text: [ID:n0001493152-25-008742]Further company coverage: SHPH.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ24H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2516300853","title":"Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300853?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:25","pubTimestamp":1740781549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ24H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2514528228","title":"Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2514528228","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514528228?lang=en_us&edition=fundamental","pubTime":"2025-02-26 23:48","pubTimestamp":1740584908,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43977530/shuttle-pharmaceuticals-fy24-eps-3-30-vs-3-53-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHPH"],"gpt_icon":0},{"id":"2514033854","title":"Shuttle Pharma Provides Corporate Update and Reports 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514033854","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514033854?lang=en_us&edition=fundamental","pubTime":"2025-02-26 23:45","pubTimestamp":1740584700,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Feb. 26, 2025  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.Shuttle Pharma’s recent highlights include the following:. Accelerated patient enrollment of the Company’s key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma with 40% enrollment in the initial randomized portion. As of today, a total of 16 of the initial 40 patients have been enrolled, with 8 of the 16 patients having completed all seven cycles.Management has made significant investments into the business, including the Company’s Chief Executive Officer, Dr. Anatoly Dritschilo, providing $237,500 along with other investors in a recent financing transaction.“We have also made significant prog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-provides-corporate-reports-154500122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2505276017","title":"Shuttle reaches milestone in enrollment for Phase 2 trial of Ropidoxuridine","url":"https://stock-news.laohu8.com/highlight/detail?id=2505276017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505276017?lang=en_us&edition=fundamental","pubTime":"2025-01-21 22:15","pubTimestamp":1737468945,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (SHPH) announced that it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Rop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shuttle-reaches-milestone-in-enrollment-for-phase-2-trial-of-ropidoxuridine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shuttle-reaches-milestone-in-enrollment-for-phase-2-trial-of-ropidoxuridine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2505275540","title":"Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505275540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505275540?lang=en_us&edition=fundamental","pubTime":"2025-01-21 22:00","pubTimestamp":1737468002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUAWM0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2505410275","title":"Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2505410275","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505410275?lang=en_us&edition=fundamental","pubTime":"2025-01-21 22:00","pubTimestamp":1737468000,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Jan. 21, 2025  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , announced today that it has achieved 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma.The Phase 2 trial design is to initially randomize 40 patients into two different dose levels, with 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to determine an optimal dose for use in glioblastoma patients. Once the optimal dose is identified, 14 additional patients will be enrolled at the optimal dose to reach statistical significance with the end-point demonstrating survival as compared to historical controls. The Phase 2 clinical trial is being conducted on patients presenting with the most aggressive form of brain tumors– IDH wild-type, methylation n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-reaches-milestone-patient-140000390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2492176618","title":"Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2492176618","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492176618?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:11","pubTimestamp":1734617492,"startTime":"0","endTime":"0","summary":"Shuttle Pharmaceuticals (SHPH) announced a sponsored research agreement with the University of California, San Francisco, UCSF, to advance pre-clin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-enters-into-sponsored-research-agreement-with-ucsf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/shuttle-pharmaceuticals-enters-into-sponsored-research-agreement-with-ucsf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SHPH","BK4139"],"gpt_icon":0},{"id":"2492944175","title":"Shuttle Pharma Enters Into Sponsored Research Agreement With the University of California, San Francisco to Advance Psma Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2492944175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492944175?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA32X4XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SHPH"],"gpt_icon":0},{"id":"2492409171","title":"Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2492409171","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492409171?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:00","pubTimestamp":1734616800,"startTime":"0","endTime":"0","summary":"GAITHERSBURG, Md., Dec. 19, 2024  -- Shuttle Pharmaceuticals Holdings, Inc.  , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy , today announced a sponsored research agreement with the University of California, San Francisco  to advance pre-clinical development of Shuttle Diagnostics, Inc.’s ligand to the prostate-specific membrane antigen  as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.Founded in 2012 by faculty members of theGeorgetown UniversityMedical Center, Shuttle Pharma is","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bsZFl8YAjLNtWtfWVxgmQA--~B/aD00NDQ7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6069b9284cf78aa5773f84bd4df49949"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shuttle-pharma-enters-sponsored-research-140000401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SHPH"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SHPH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-13","symbol":"SHPH","defaultRemindTime":1723555800000,"type":"split","dateTimestamp":1723521600000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SHPH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SHPH\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SHPH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SHPH","date":"2025-04-25","current":-0.20296,"percent":0.986777,"low":-282.45653,"twenty":-8.291085,"median":-1.29342,"eighty":-0.368296,"high":-0.17162,"avg":-7.848262,"sd":28.083216,"marketCap":1856031},"quantilePoints":[{"date":"2022-09-02","current":-80.316838,"twenty":-252.442828,"median":-207.422276,"eighty":-131.159013,"marketCap":157029297},{"date":"2022-09-09","current":-233.475315,"twenty":-230.586961,"median":-207.422276,"eighty":-174.21591,"marketCap":456472959},{"date":"2022-09-16","current":-54.096471,"twenty":-240.214809,"median":-213.22791,"eighty":-114.354765,"marketCap":105765255},{"date":"2022-09-23","current":-35.140877,"twenty":-231.91079,"median":-171.496043,"eighty":-51.64137,"marketCap":68704737},{"date":"2022-09-30","current":-28.051587,"twenty":-224.32886,"median":-68.891528,"eighty":-35.593125,"marketCap":54844303},{"date":"2022-10-07","current":-23.162421,"twenty":-216.71129,"median":-51.027595,"eighty":-28.467166,"marketCap":45285383},{"date":"2022-10-14","current":-21.023412,"twenty":-202.956897,"median":-37.836406,"eighty":-23.309096,"marketCap":41103356},{"date":"2022-10-21","current":-16.134246,"twenty":-182.375512,"median":-34.346388,"eighty":-19.764451,"marketCap":31544436},{"date":"2022-10-28","current":-17.173194,"twenty":-157.210724,"median":-29.090535,"eighty":-18.701058,"marketCap":33575706},{"date":"2022-11-04","current":-12.03957,"twenty":-96.118924,"median":-24.201369,"eighty":-16.170915,"marketCap":23538840},{"date":"2022-11-11","current":-11.428424,"twenty":-75.746714,"median":-23.009635,"eighty":-15.963125,"marketCap":22343975},{"date":"2022-11-18","current":-8.688263,"twenty":-56.792269,"median":-20.106693,"eighty":-13.665217,"marketCap":23776187},{"date":"2022-11-25","current":-8.092496,"twenty":-54.096471,"median":-19.678891,"eighty":-11.428424,"marketCap":22145820},{"date":"2022-12-02","current":-11.964979,"twenty":-51.027595,"median":-18.976073,"eighty":-10.511706,"marketCap":32743207},{"date":"2022-12-09","current":-13.65646,"twenty":-38.807751,"median":-16.928735,"eighty":-10.773446,"marketCap":37372091},{"date":"2022-12-16","current":-11.890509,"twenty":-38.270696,"median":-16.103689,"eighty":-10.817279,"marketCap":32539411},{"date":"2022-12-23","current":-10.425916,"twenty":-37.402116,"median":-16.012017,"eighty":-10.773446,"marketCap":28531425},{"date":"2022-12-30","current":-9.730855,"twenty":-35.593125,"median":-15.706444,"eighty":-10.207468,"marketCap":26629330},{"date":"2023-01-06","current":-8.688263,"twenty":-34.664184,"median":-14.85084,"eighty":-9.581913,"marketCap":23776187},{"date":"2023-01-13","current":-11.617449,"twenty":-34.126376,"median":-14.028433,"eighty":-9.045723,"marketCap":31792159},{"date":"2023-01-20","current":-10.823093,"twenty":-32.439613,"median":-13.611947,"eighty":-9.224453,"marketCap":29618336},{"date":"2023-01-27","current":-10.227327,"twenty":-29.298324,"median":-13.355101,"eighty":-9.432971,"marketCap":27987969},{"date":"2023-02-03","current":-10.0908,"twenty":-26.780404,"median":-12.151216,"eighty":-9.432971,"marketCap":27614351},{"date":"2023-02-10","current":-9.693133,"twenty":-24.604725,"median":-12.014627,"eighty":-9.532265,"marketCap":26526101},{"date":"2023-02-17","current":-9.494299,"twenty":-24.07914,"median":-11.753979,"eighty":-9.457502,"marketCap":25981976},{"date":"2023-02-24","current":-8.450423,"twenty":-23.749121,"median":-11.617449,"eighty":-9.322967,"marketCap":23125319},{"date":"2023-03-03","current":-8.84809,"twenty":-23.101307,"median":-11.428424,"eighty":-9.246599,"marketCap":24213569},{"date":"2023-03-10","current":-6.859756,"twenty":-22.490162,"median":-11.195448,"eighty":-8.986146,"marketCap":18772318},{"date":"2023-03-17","current":-6.537502,"twenty":-20.840068,"median":-10.823093,"eighty":-8.858032,"marketCap":19798484},{"date":"2023-03-24","current":-5.680864,"twenty":-20.021133,"median":-10.795362,"eighty":-8.688263,"marketCap":17204200},{"date":"2023-03-31","current":-5.996467,"twenty":-19.678891,"median":-10.723799,"eighty":-8.54925,"marketCap":18159988},{"date":"2023-04-06","current":-6.537502,"twenty":-19.678891,"median":-10.425916,"eighty":-8.450423,"marketCap":19798484},{"date":"2023-04-14","current":-6.041553,"twenty":-19.556662,"median":-10.258449,"eighty":-8.152173,"marketCap":18296530},{"date":"2023-04-21","current":-6.31207,"twenty":-19.434433,"median":-10.227327,"eighty":-7.447082,"marketCap":19115777},{"date":"2023-04-28","current":-7.303967,"twenty":-18.517714,"median":-10.084592,"eighty":-7.248493,"marketCap":22119685},{"date":"2023-05-05","current":-6.086639,"twenty":-17.173194,"median":-10.041091,"eighty":-6.988364,"marketCap":18433071},{"date":"2023-05-12","current":-5.094743,"twenty":-16.977627,"median":-9.929444,"eighty":-6.582588,"marketCap":15429163},{"date":"2023-05-18","current":-4.914398,"twenty":-16.562048,"median":-9.730855,"eighty":-6.465364,"marketCap":14882998},{"date":"2023-05-25","current":-5.861208,"twenty":-16.244252,"median":-9.693133,"eighty":-6.31207,"marketCap":17750365},{"date":"2023-06-02","current":-4.613085,"twenty":-16.122023,"median":-9.544008,"eighty":-6.266984,"marketCap":15323313},{"date":"2023-06-09","current":-4.894734,"twenty":-16.085354,"median":-9.463635,"eighty":-6.172303,"marketCap":16258867},{"date":"2023-06-15","current":-4.627749,"twenty":-16.060908,"median":-9.432971,"eighty":-6.136235,"marketCap":15372020},{"date":"2023-06-23","current":-4.983729,"twenty":-16.02424,"median":-9.345174,"eighty":-6.086639,"marketCap":16554483},{"date":"2023-06-30","current":-5.072724,"twenty":-16.012017,"median":-9.295466,"eighty":-5.996467,"marketCap":16850099},{"date":"2023-07-07","current":-4.895179,"twenty":-15.999794,"median":-9.264924,"eighty":-5.996467,"marketCap":16260345},{"date":"2023-07-14","current":-4.583251,"twenty":-15.950902,"median":-9.066183,"eighty":-5.861659,"marketCap":15224212},{"date":"2023-07-21","current":-4.449758,"twenty":-15.853119,"median":-9.016535,"eighty":-5.861208,"marketCap":14780789},{"date":"2023-07-27","current":-4.000778,"twenty":-15.755336,"median":-8.986146,"eighty":-5.838665,"marketCap":13289407},{"date":"2023-08-03","current":-4.005227,"twenty":-15.543988,"median":-8.961322,"eighty":-5.69439,"marketCap":13304188},{"date":"2023-08-11","current":-3.629668,"twenty":-14.8855,"median":-8.897799,"eighty":-5.635777,"marketCap":12056689},{"date":"2023-08-18","current":-2.349846,"twenty":-14.799928,"median":-8.768116,"eighty":-5.251943,"marketCap":11534927},{"date":"2023-08-25","current":-2.292603,"twenty":-14.488296,"median":-8.688263,"eighty":-5.069521,"marketCap":11253932},{"date":"2023-09-01","current":-2.371448,"twenty":-14.045184,"median":-8.613792,"eighty":-4.919365,"marketCap":11640968},{"date":"2023-09-08","current":-2.163437,"twenty":-14.000515,"median":-8.514755,"eighty":-4.894289,"marketCap":10619886},{"date":"2023-09-15","current":-2.17145,"twenty":-13.65646,"median":-8.450423,"eighty":-4.761241,"marketCap":10659219},{"date":"2023-09-20","current":-2.132028,"twenty":-13.62085,"median":-8.291085,"eighty":-4.690223,"marketCap":10465701},{"date":"2023-09-28","current":-1.778826,"twenty":-13.585239,"median":-8.291085,"eighty":-4.666573,"marketCap":8731906},{"date":"2023-10-03","current":-1.849979,"twenty":-13.544826,"median":-8.201881,"eighty":-4.64388,"marketCap":9081182},{"date":"2023-10-13","current":-2.036836,"twenty":-13.499611,"median":-8.152173,"eighty":-4.627749,"marketCap":9998426},{"date":"2023-10-19","current":-1.891005,"twenty":-13.434537,"median":-8.022918,"eighty":-4.613667,"marketCap":9282567},{"date":"2023-10-27","current":-1.602059,"twenty":-13.394819,"median":-7.799506,"eighty":-4.565452,"marketCap":7864189},{"date":"2023-11-03","current":-1.628108,"twenty":-12.967853,"median":-7.447082,"eighty":-4.46048,"marketCap":7992062},{"date":"2023-11-10","current":-1.627783,"twenty":-12.441592,"median":-7.330403,"eighty":-4.003447,"marketCap":7990464},{"date":"2023-11-17","current":-1.441985,"twenty":-12.128887,"median":-7.198846,"eighty":-3.713768,"marketCap":8223832},{"date":"2023-11-24","current":-1.430714,"twenty":-12.03957,"median":-6.988364,"eighty":-3.02365,"marketCap":8159553},{"date":"2023-12-01","current":-1.402381,"twenty":-12.029593,"median":-6.833887,"eighty":-2.449276,"marketCap":7997962},{"date":"2023-12-08","current":-1.402661,"twenty":-11.994768,"median":-6.582588,"eighty":-2.374562,"marketCap":7999562},{"date":"2023-12-15","current":-1.374608,"twenty":-11.935191,"median":-6.44733,"eighty":-2.344923,"marketCap":7839571},{"date":"2023-12-22","current":-1.346274,"twenty":-11.781285,"median":-6.31207,"eighty":-2.270039,"marketCap":7677980},{"date":"2023-12-29","current":-1.290729,"twenty":-11.617449,"median":-6.266984,"eighty":-2.243565,"marketCap":7361197},{"date":"2024-01-05","current":-1.51291,"twenty":-11.617449,"median":-6.266984,"eighty":-2.236193,"marketCap":8628328},{"date":"2024-01-12","current":-1.297181,"twenty":-11.617449,"median":-6.165541,"eighty":-2.093951,"marketCap":7397995},{"date":"2024-01-19","current":-1.24921,"twenty":-11.577731,"median":-6.131726,"eighty":-1.955106,"marketCap":7124410},{"date":"2024-01-26","current":-1.151585,"twenty":-11.482262,"median":-6.086639,"eighty":-1.86556,"marketCap":6567640},{"date":"2024-02-02","current":-1.094076,"twenty":-11.428424,"median":-5.996467,"eighty":-1.665229,"marketCap":6239658},{"date":"2024-02-09","current":-1.06462,"twenty":-11.345163,"median":-5.996467,"eighty":-1.626611,"marketCap":6071667},{"date":"2024-02-16","current":-1.034916,"twenty":-11.200412,"median":-5.90652,"eighty":-1.580177,"marketCap":5902261},{"date":"2024-02-23","current":-1.011811,"twenty":-11.153493,"median":-5.861208,"eighty":-1.532376,"marketCap":5770492},{"date":"2024-03-01","current":-1.103102,"twenty":-11.032592,"median":-5.748493,"eighty":-1.447546,"marketCap":6291138},{"date":"2024-03-08","current":-1.155229,"twenty":-10.823093,"median":-5.680864,"eighty":-1.428518,"marketCap":6588421},{"date":"2024-03-15","current":-1.225106,"twenty":-10.82193,"median":-5.635777,"eighty":-1.403856,"marketCap":6986940},{"date":"2024-03-22","current":-1.273569,"twenty":-10.808512,"median":-5.361959,"eighty":-1.402379,"marketCap":7263332},{"date":"2024-03-28","current":-1.069946,"twenty":-10.773446,"median":-5.184915,"eighty":-1.388635,"marketCap":7053855},{"date":"2024-04-05","current":-1.089052,"twenty":-10.737009,"median":-5.072724,"eighty":-1.374608,"marketCap":7179816},{"date":"2024-04-12","current":-1.07504,"twenty":-10.723799,"median":-4.985424,"eighty":-1.348238,"marketCap":7087444},{"date":"2024-04-19","current":-1.022562,"twenty":-10.511706,"median":-4.914398,"eighty":-1.337967,"marketCap":6741470},{"date":"2024-04-26","current":-1.016958,"twenty":-10.425916,"median":-4.894512,"eighty":-1.303718,"marketCap":6704521},{"date":"2024-05-03","current":-1.120895,"twenty":-10.376268,"median":-4.805739,"eighty":-1.287924,"marketCap":7389752},{"date":"2024-05-10","current":-1.077012,"twenty":-10.276974,"median":-4.739215,"eighty":-1.273569,"marketCap":7100444},{"date":"2024-05-17","current":-0.942057,"twenty":-10.239925,"median":-4.672246,"eighty":-1.237147,"marketCap":6922854},{"date":"2024-05-24","current":-0.97619,"twenty":-10.227327,"median":-4.635815,"eighty":-1.195521,"marketCap":7173684},{"date":"2024-05-31","current":-1.215374,"twenty":-10.227327,"median":-4.621871,"eighty":-1.189992,"marketCap":8931363},{"date":"2024-06-07","current":-1.065455,"twenty":-10.197638,"median":-4.583251,"eighty":-1.186002,"marketCap":7829660},{"date":"2024-06-14","current":-1.005487,"twenty":-10.130566,"median":-4.529967,"eighty":-1.177893,"marketCap":7388978},{"date":"2024-06-21","current":-0.923318,"twenty":-10.085834,"median":-4.467628,"eighty":-1.159877,"marketCap":6785144},{"date":"2024-06-28","current":-0.869759,"twenty":-10.080868,"median":-4.449758,"eighty":-1.149523,"marketCap":6391559},{"date":"2024-07-05","current":-0.881203,"twenty":-10.078385,"median":-4.027031,"eighty":-1.124633,"marketCap":6475658},{"date":"2024-07-12","current":-0.963372,"twenty":-10.056009,"median":-3.908223,"eighty":-1.110142,"marketCap":7079492},{"date":"2024-07-15","current":-0.971154,"twenty":-10.04855,"median":-3.815668,"eighty":-1.102764,"marketCap":7136680},{"date":"2024-08-02","current":-0.845955,"twenty":-10.041091,"median":-3.798091,"eighty":-1.101412,"marketCap":6216632},{"date":"2024-08-09","current":-0.792396,"twenty":-9.991383,"median":-3.677725,"eighty":-1.09542,"marketCap":5823046},{"date":"2024-08-16","current":-0.597959,"twenty":-9.941832,"median":-3.629668,"eighty":-1.093784,"marketCap":4394195},{"date":"2024-08-23","current":-0.612264,"twenty":-9.899462,"median":-2.514716,"eighty":-1.087676,"marketCap":4499320},{"date":"2024-08-30","current":-0.527863,"twenty":-9.763077,"median":-2.43587,"eighty":-1.075611,"marketCap":3879086},{"date":"2024-09-06","current":-0.634062,"twenty":-9.708222,"median":-2.411832,"eighty":-1.07244,"marketCap":4562394},{"date":"2024-09-13","current":-0.495187,"twenty":-9.693133,"median":-2.371769,"eighty":-1.0701,"marketCap":3563121},{"date":"2024-09-20","current":-0.501377,"twenty":-9.685977,"median":-2.349846,"eighty":-1.065245,"marketCap":3607660},{"date":"2024-09-27","current":-0.417814,"twenty":-9.598888,"median":-2.30943,"eighty":-1.058966,"marketCap":3006383},{"date":"2024-10-04","current":-0.363653,"twenty":-9.514183,"median":-2.259911,"eighty":-1.037615,"marketCap":2616667},{"date":"2024-10-11","current":-0.343536,"twenty":-9.457502,"median":-2.243565,"eighty":-1.032141,"marketCap":2471915},{"date":"2024-10-18","current":-0.374485,"twenty":-9.432971,"median":-2.227539,"eighty":-1.018181,"marketCap":2694610},{"date":"2024-10-25","current":-0.397697,"twenty":-9.380293,"median":-2.147733,"eighty":-1.014539,"marketCap":2861632},{"date":"2024-10-31","current":-0.557086,"twenty":-9.325291,"median":-2.011996,"eighty":-1.00644,"marketCap":4008511},{"date":"2024-11-08","current":-0.362106,"twenty":-9.295466,"median":-1.955106,"eighty":-0.990068,"marketCap":2605532},{"date":"2024-11-15","current":-0.259375,"twenty":-9.295466,"median":-1.889968,"eighty":-0.98435,"marketCap":2382837},{"date":"2024-11-22","current":-0.213803,"twenty":-9.271032,"median":-1.778826,"eighty":-0.973168,"marketCap":1964170},{"date":"2024-11-29","current":-0.338294,"twenty":-9.204594,"median":-1.672067,"eighty":-0.960397,"marketCap":3107851},{"date":"2024-12-06","current":-0.318427,"twenty":-9.077738,"median":-1.628434,"eighty":-0.946292,"marketCap":2925338},{"date":"2024-12-13","current":-0.279252,"twenty":-9.034768,"median":-1.625829,"eighty":-0.917092,"marketCap":2565443},{"date":"2024-12-20","current":-0.271274,"twenty":-8.986146,"median":-1.602059,"eighty":-0.914507,"marketCap":2492144},{"date":"2024-12-27","current":-0.317749,"twenty":-8.986146,"median":-1.564286,"eighty":-0.890244,"marketCap":2919107},{"date":"2025-01-03","current":-0.339491,"twenty":-8.946428,"median":-1.540191,"eighty":-0.870125,"marketCap":3118846},{"date":"2025-01-10","current":-0.342722,"twenty":-8.936499,"median":-1.499865,"eighty":-0.842888,"marketCap":3148531},{"date":"2025-01-17","current":-0.351339,"twenty":-8.913279,"median":-1.444741,"eighty":-0.769782,"marketCap":3227694},{"date":"2025-01-24","current":-0.367017,"twenty":-8.877915,"median":-1.430714,"eighty":-0.667768,"marketCap":3371725},{"date":"2025-01-31","current":-0.313321,"twenty":-8.823877,"median":-1.422327,"eighty":-0.613408,"marketCap":2878427},{"date":"2025-02-07","current":-0.273269,"twenty":-8.772004,"median":-1.407512,"eighty":-0.576788,"marketCap":2510473},{"date":"2025-02-14","current":-0.275662,"twenty":-8.72451,"median":-1.402661,"eighty":-0.558558,"marketCap":2532459},{"date":"2025-02-21","current":-0.237364,"twenty":-8.688263,"median":-1.402379,"eighty":-0.538449,"marketCap":2180626},{"date":"2025-02-28","current":-0.24583,"twenty":-8.688263,"median":-1.397051,"eighty":-0.521185,"marketCap":2248061},{"date":"2025-03-07","current":-0.245179,"twenty":-8.678334,"median":-1.384324,"eighty":-0.496425,"marketCap":2242111},{"date":"2025-03-14","current":-0.292876,"twenty":-8.628686,"median":-1.374608,"eighty":-0.449382,"marketCap":2678292},{"date":"2025-03-21","current":-0.277548,"twenty":-8.579039,"median":-1.36535,"eighty":-0.421528,"marketCap":2538120},{"date":"2025-03-28","current":-0.270226,"twenty":-8.529495,"median":-1.347116,"eighty":-0.412862,"marketCap":2471162},{"date":"2025-04-04","current":-0.273853,"twenty":-8.490087,"median":-1.339596,"eighty":-0.403578,"marketCap":2504328},{"date":"2025-04-11","current":-0.28398,"twenty":-8.481824,"median":-1.316257,"eighty":-0.387762,"marketCap":2596942},{"date":"2025-04-17","current":-0.175178,"twenty":-8.450423,"median":-1.303718,"eighty":-0.374485,"marketCap":1601969},{"date":"2025-04-25","current":-0.20296,"twenty":-8.291085,"median":-1.29342,"eighty":-0.368296,"marketCap":1856031}],"updateTime":1745739831583}}}